Telomerase regulation in hematological cancers: A matter of stemness?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 4, 2009, Pages 229-239

  Deville, Laure ^a   Hillion, Josette ^a   Ségal Bendirdjian, Evelyne ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Anti telomerase strategies; Leukemia; Stem cell; Telomerase; Telomere

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ACUTE LEUKEMIA; B CELL LEUKEMIA; CANCER RESEARCH; CANCER STEM CELL; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; CHROMOSOME SIZE; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPIGENETICS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; TELOMERE; TRANSCRIPTION REGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; TELOMERASE; TELOMERE;

EID: 64249162002     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.01.016     Document Type: Review

References (200)

1. Blackburn E.H. Telomerases. Annu. Rev. Biochem. 61 (1992) 113-129
2. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., and Moore M.A. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 90 (1997) 182-193
3. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., and Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9857-9860
4. de Lange T. Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2882-2885
5. Greider C.W., and Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43 (1985) 405-413
6. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M.A., Shay J.W., Ishioka S., and Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155 (1995) 3711-3715
7. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
8. Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V., and Cech T.R. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276 (1997) 561-567
9. Morrison S.J., Prowse K.R., Ho P., and Weissman I.L. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 5 (1996) 207-216
10. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., and Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18 (1996) 173-179
11. Pendino F., Tarkanyi I., Dudognon C., Hillion J., Lanotte M., Aradi J., and Segal-Bendirdjian E. Telomeres and telomerase: pharmacological targets for new anticancer strategies?. Current Cancer Drug Targets 6 (2006) 147-180
12. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 269 (1995) 1236-1241
13. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., and Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
14. Cristofari G., and Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J. 25 (2006) 565-574
15. Cong Y.S., Wright W.E., and Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 66 (2002) 407-425
16. Dudognon C., Pendino F., Hillion J., Saumet A., Lanotte M., and Segal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 23 (2004) 7469-7474
17. Stewart S.A., Hahn W.C., O'Connor B.F., Banner E.N., Lundberg A.S., Modha P., Mizuno H., Brooks M.W., Fleming M., Zimonjic D.B., Popescu N.C., and Weinberg R.A. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12606-12611
18. Imamura S., Uchiyama J., Koshimizu E., Hanai J., Raftopoulou C., Murphey R.D., Bayliss P.E., Imai Y., Burns C.E., Masutomi K., Gagos S., Zon L.I., Roberts T.M., and Kishi S. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS One 3 (2008) e3364
19. Cerezo A., Stark H.J., Moshir S., and Boukamp P. Constitutive overexpression of human telomerase reverse transcriptase but not c-myc blocks terminal differentiation in human HaCaT skin keratinocytes. J. Invest. Dermatol. 121 (2003) 110-119
20. Liu L., DiGirolamo C.M., Navarro P.A., Blasco M.A., and Keefe D.L. Telomerase deficiency impairs differentiation of mesenchymal stem cells. Exp. Cell Res. 294 (2004) 1-8
21. Wang J., Feng H., Huang X.Q., Xiang H., Mao Y.W., Liu J.P., Yan Q., Liu W.B., Liu Y., Deng M., Gong L., Sun S., Luo C., Liu S.J., Zhang X.J., and Li D.W. Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway. J. Biol. Chem. 280 (2005) 22776-22787
22. Lee M.K., Hande M.P., and Sabapathy K. Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to differentiation- and stress-induced p53-dependent apoptosis. J. Cell Sci. 118 (2005) 819-829
23. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., and Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 315 (2007) 1850-1853
24. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19 (2005) 2100-2110
25. Smogorzewska A., and de Lange T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 73 (2004) 177-208
26. Cong Y.S., Wen J., and Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8 (1999) 137-142
27. Horikawa I., Cable P.L., Afshari C., and Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59 (1999) 826-830
28. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., and Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59 (1999) 551-557
29. Dessain S.K., Yu H., Reddel R.R., Beijersbergen R.L., and Weinberg R.A. Methylation of the human telomerase gene CpG island. Cancer Res. 60 (2000) 537-541
30. Shin K.H., Kang M.K., Dicterow E., and Park N.H. Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br. J. Cancer 89 (2003) 1473-1478
31. Devereux T.R., Horikawa I., Anna C.H., Annab L.A., Afshari C.A., and Barrett J.C. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 59 (1999) 6087-6090
32. Guilleret I., Yan P., Grange F., Braunschweig R., Bosman F.T., and Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer 101 (2002) 335-341
33. Renaud S., Loukinov D., Abdullaev Z., Guilleret I., Bosman F.T., Lobanenkov V., and Benhattar J. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 35 (2007) 7372-7388
34. Zinn R.L., Pruitt K., Eguchi S., Baylin S.B., and Herman J.G. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 67 (2007) 194-201
35. Renaud S., Loukinov D., Bosman F.T., Lobanenkov V., and Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 33 (2005) 6850-6860
36. Chatagnon A., Bougel S., Perriaud L., Lachuer J., Benhattar J., and Dante R. Specific association between the Methyl-CpG binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30 (2009) 28-34
37. Cong Y.S., and Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J. Biol. Chem. 275 (2000) 35665-35668
38. Hou M., Wang X., Popov N., Zhang A., Zhao X., Zhou R., Zetterberg A., Bjorkholm M., Henriksson M., Gruber A., and Xu D. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell Res. 274 (2002) 25-34
39. Horikawa I., and Barrett J.C. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24 (2003) 1167-1176
40. Bellon M., and Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. J. Natl. Cancer Inst. 100 (2008) 98-108
41. Ferber M.J., Montoya D.P., Yu C., Aderca I., McGee A., Thorland E.C., Nagorney D.M., Gostout B.S., Burgart L.J., Boix L., Bruix J., McMahon B.J., Cheung T.H., Chung T.K., Wong Y.F., Smith D.I., and Roberts L.R. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22 (2003) 3813-3820
42. Paterlini-Brechot P., Saigo K., Murakami Y., Chami M., Gozuacik D., Mugnier C., Lagorce D., and Brechot C. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22 (2003) 3911-3916
43. Yang F., Xian R.R., Li Y., Polony T.S., and Beemon K.L. Telomerase reverse transcriptase expression elevated by avian leukosis virus integration in B cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 18952-18957
44. Colgin L.M., Wilkinson C., Englezou A., Kilian A., Robinson M.O., and Reddel R.R. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2 (2000) 426-432
45. Hisatomi H., Ohyashiki K., Ohyashiki J.H., Nagao K., Kanamaru T., Hirata H., Hibi N., and Tsukada Y. Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia 5 (2003) 193-197
46. Kilian A., Bowtell D.D., Abud H.E., Hime G.R., Venter D.J., Keese P.K., Duncan E.L., Reddel R.R., and Jefferson R.A. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6 (1997) 2011-2019
47. Ulaner G.A., Hu J.F., Vu T.H., Giudice L.C., and Hoffman A.R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58 (1998) 4168-4172
48. Yi X., White D.M., Aisner D.L., Baur J.A., Wright W.E., and Shay J.W. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2 (2000) 433-440
49. Saeboe-Larssen S., Fossberg E., and Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissus. BMC Mol. Biol. 7 (2006)
50. Anderson C.J., Hoare S.F., Ashcroft M., Bilsland A.E., and Keith W.N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25 (2006) 61-69
51. Brenner C.A., Wolny Y.M., Adler R.R., and Cohen J. Alternative splicing of the telomerase catalytic subunit in human oocytes and embryos. Mol. Hum. Reprod. 5 (1999) 845-850
52. Drummond M.W., Hoare S.F., Monaghan A., Graham S.M., Alcorn M.J., Keith W.N., and Holyoake T.L. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 19 (2005) 381-389
53. Jalink M., Ge Z., Liu C., Bjorkholm M., Gruber A., and Xu D. Human normal T lymphocytes and lymphoid cell lines do express alternative splicing variants of human telomerase reverse transcriptase (hTERT) mRNA. Biochem. Biophys. Res. Commun. 353 (2007) 999-1003
54. Krams M., Claviez A., Heidorn K., Krupp G., Parwaresch R., Harms D., and Rudolph P. Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am. J. Pathol. 159 (2001) 1925-1932
55. Ulaner G.A., Hu J.F., Vu T.H., Giudice L.C., and Hoffman A.R. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int. J. Cancer 91 (2001) 644-649
56. Villa R., Porta C.D., Folini M., Daidone M.G., and Zaffaroni N. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J. Invest. Dermatol. 116 (2001) 867-873
57. Zaffaroni N., Villa R., Pastorino U., Cirincione R., Incarbone M., Alloisio M., Curto M., Pilotti S., and Daidone M.G. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin. Cancer Res. 11 (2005) 2832-2839
58. Gomez D., Aouali N., Renaud A., Douarre C., Shin-Ya K., Tazi J., Martinez S., Trentesaux C., Morjani H., and Riou J.F. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase. Cancer Res. 63 (2003) 6149-6153
59. Rohde V., Sattler H.P., Bund T., Bonkhoff H., Fixemer T., Bachmann C., Lensch R., Unteregger G., Stoeckle M., and Wullich B. Expression of the human telomerase reverse transcriptase is not related to telomerase activity in normal and malignant renal tissue. Clin. Cancer Res. 6 (2000) 4803-4809
60. Kang S.S., Kwon T., Kwon D.Y., and Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274 (1999) 13085-13090
61. Kharbanda S., Kumar V., Dhar S., Pandey P., Chen C., Majumder P., Yuan Z.M., Whang Y., Strauss W., Pandita T.K., Weaver D., and Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol. 10 (2000) 568-575
62. Li H., Zhao L., Yang Z., Funder J.W., and Liu J.P. Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J. Biol. Chem. 273 (1998) 33436-33442
63. Li H., Zhao L.L., Funder J.W., and Liu J.P. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem. 272 (1997) 16729-16732
64. Evans S.K., and Lundblad V. Positive and negative regulation of telomerase access to the telomere. J. Cell Sci. 113 Pt. 19 (2000) 3357-3364
65. Le S., Sternglanz R., and Greider C.W. Identification of two RNA-binding proteins associated with human telomerase RNA. Mol. Biol. Cell 11 (2000) 999-1010
66. Pogacic V., Dragon F., and Filipowicz W. Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol. Cell. Biol. 20 (2000) 9028-9040
67. Liu K., Hodes R.J., and Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol. 166 (2001) 4826-4830
68. Yang Y., Chen Y., Zhang C., Huang H., and Weissman S.M. Nucleolar localization of hTERT protein is associated with telomerase function. Exp. Cell Res. 277 (2002) 201-209
69. Wong J.M., Kusdra L., and Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat. Cell Biol. 4 (2002) 731-736
70. Zhu Y., Tomlinson R.L., Lukowiak A.A., Terns R.M., and Terns M.P. Telomerase RNA accumulates in Cajal bodies in human cancer cells. Mol. Biol. Cell 15 (2004) 81-90
71. Tomlinson R.L., Ziegler T.D., Supakorndej T., Terns R.M., and Terns M.P. Cell cycle-regulated trafficking of human telomerase to telomeres. Mol. Biol. Cell 17 (2006) 955-965
72. Tomlinson R.L., Abreu E.B., Ziegler T., Ly H., Counter C.M., Terns R.M., and Terns M.P. Telomerase reverse transcriptase is required for the localization of telomerase RNA to Cajal bodies and telomeres in human cancer cells. Mol. Biol. Cell 19 (2008) 3793-3800
73. Lin J., Jin R., Zhang B., Chen H., Bai Y.X., Yang P.X., Han S.W., Xie Y.H., Huang P.T., Huang C., and Huang J.J. Nucleolar localization of TERT is unrelated to telomerase function in human cells. J. Cell Sci. 121 (2008) 2169-2176
74. Jady B.E., Bertrand E., and Kiss T. Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal. J. Cell Biol. 164 (2004) 647-652
75. Jady B.E., Richard P., Bertrand E., and Kiss T. Cell cycle-dependent recruitment of telomerase RNA and Cajal bodies to human telomeres. Mol. Biol. Cell 17 (2006) 944-954
76. Holt S.E., Aisner D.L., Baur J., Tesmer V.M., Dy M., Ouellette M., Trager J.B., Morin G.B., Toft D.O., Shay J.W., Wright W.E., and White M.A. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13 (1999) 817-826
77. Santos J.H., Meyer J.N., Skorvaga M., Annab L.A., and Van Houten B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell 3 (2004) 399-411
78. Santos J.H., Meyer J.N., and Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum. Mol. Genet. 15 (2006) 1757-1768
79. Wu Y.L., Dudognon C., Nguyen E., Hillion J., Pendino F., Tarkanyi I., Aradi J., Lanotte M., Tong J.H., Chen G.Q., and Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J. Cell Sci. 119 (2006) 2797-2806
80. Lantuejoul S., Salon C., Soria J.C., and Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int. J. Cancer 120 (2007) 1835-1841
81. van Steensel B., and de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 385 (1997) 740-743
82. van Steensel B., Smogorzewska A., and de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 92 (1998) 401-413
83. Baumann P., and Cech T.R. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 292 (2001) 1171-1175
84. Wang F., Podell E.R., Zaug A.J., Yang Y., Baciu P., Cech T.R., and Lei M. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 445 (2007) 506-510
85. Ghosh U., Das N., and Bhattacharyya N.P. Inhibition of telomerase activity by reduction of poly(ADP-ribosyl)ation of TERT and TEP1/TP1 expression in HeLa cells with knocked down poly(ADP-ribose) polymerase-1 (PARP-1) gene. Mutat. Res. 615 (2007) 66-74
86. Azzalin C.M., Reichenbach P., Khoriauli L., Giulotto E., and Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318 (2007) 798-801
87. Schoeftner S., and Blasco M.A. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat. Cell Biol. 10 (2008) 228-236
88. Ju Z., Jiang H., Jaworski M., Rathinam C., Gompf A., Klein C., Trumpp A., and Rudolph K.L. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat. Med. 13 (2007) 742-747
89. Ju Z., and Lenhard Rudolph K. Telomere dysfunction and stem cell ageing. Biochimie 90 (2008) 24-32
90. Rudolph K.L., Millard M., Bosenberg M.W., and DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28 (2001) 155-159
91. Gurkan E., Tanriverdi K., and Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk. Res. 29 (2005) 1131-1139
92. Ohyashiki K., Iwama H., Yahata N., Tauchi T., Kawakubo K., Shimamoto T., and Ohyashiki J.H. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk. Lymphoma 42 (2001) 291-299
93. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W., and Ohyashiki K. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 5 (1999) 1155-1160
94. Swiggers S.J.J., Kuijpers M.A., de Cort M.J.M., Beverloo H.B., and Zijlmans J.M. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 45 (2006) 247-256
95. Hartmann U., Brummendorf T.H., Balabanov S., Thiede C., Illme T., and Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 90 (2005) 307-316
96. Ghaffari S.H., Shayan-Asl N., Jamialahmadi A.H., Alimoghaddam K., and Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann. Oncol. 19 (2008) 1927-1934
97. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
98. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
99. Brummendorf T.H., Holyoake T.L., Rufer N., et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myelogenous leukemia measured by flow cytometry. Blood 95 (2000) 1883-1890
100. Brummendorf T.H., Ersoz I., Hartmann U., Bartolovic K., Balabanov S., Wahl A., Paschka P., Kreil S., Lahaye T., Berger U., Gschaidmeier H., Bokemeyer C., Hehlmann R., Dietz K., Lansdorp P.M., Kanz L., and Hochhaus A. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood 101 (2003) 375-376
101. Bock O., Serinsoz E., Schlue J., and Kreipe H. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk. Res. 28 (2004) 457-460
102. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., and Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 11 (1997) 190-194
103. Tatematsu K., Nakayama J., Danbara M., Shionoya S., Sato H., Omine M., and Ishikawa F. A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 13 (1996) 2265-2274
104. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Faderl S., Giles F.J., Keating M., and Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 97 (2003) 1248-1252
105. Boultwood J., Peniket A., Watkins F., et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 96 (2000) 358-361
106. Campbell L.J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., Littlewood T.J., Wainscoat J.S., and Boultwood J. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 20 (2006) 671-679
107. Uchida N., Otsuka T., Arima F., Shigematsu H., Fukuyama T., Maeda M., Sugio Y., Itoh Y., and Niho Y. Correlation of telomerase activity with development and progression of adult T-cell leukemia. Leuk. Res. 23 (1999) 311-316
108. Bellon M., Datta A., Brown M., Pouliquen J.F., Couppie P., Kazanji M., and Nicot C. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. Int. J. Cancer 119 (2006) 2090-2097
109. Franzese O., Balestrieri E., Comandini A., Forte G., Macchi B., and Bonmassar E. Telomerase activity of human peripheral blood mononuclear cells in the course of HTLV type 1 infection in vitro. AIDS Res. Hum. Retrovir. 18 (2002) 249-251
110. Kubuki Y., Suzuki M., Sasaki H., Toyama T., Yamashita K., Maeda K., Ido A., Matsuoka H., Okayama A., Nakanishi T., and Tsubouchi H. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk. Lymphoma 46 (2005) 393-399
111. Gabet A.S., Mortreux F., Charneau P., Riou P., Duc-Dodon M., Wu Y., Jeang K.T., and Wattel E. Inactivation of hTERT transcription by Tax. Oncogene 22 (2003) 3734-3741
112. Sinha-Datta U., Horikawa I., Michishita E., Datta A., Sigler-Nicot J.C., Brown M., Kazanji M., Barrett J.C., and Nicot C. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 104 (2004) 2523-2531
113. Hara T., Matsumura-Arioka Y., Ohtani K., and Nakamura M. Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. Cancer Sci. 99 (2008) 1155-1163
114. Kuhlmann A.-S., Villaudy J., Gazzolo L., Castellazzi M., Mesnard J.-M., and Duc Dodon M. HTLV-1 HBV cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase (hTERT). Retrovirology 4 (2007)
115. Chiorazzi N., and Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21 (2003) 841-894
116. Counter C.M., Gupta J., Harley C.B., Leber B., and Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85 (1995) 2315-2320
117. Damle R.N., Batliwalla F.M., Ghiotto F., Valetto A., Albesiano E., Sison C., Allen S.L., Kolitz J., Vinciguerra V.P., Kudalkar P., Wasil T., Rai K.R., Ferrarini M., Gregersen P.K., and Chiorazzi N. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103 (2004) 375-382
118. Poncet D., Beelleville A., t'Kint de Roodenbeke C., A. R.d.C., Ben Simon E., Merle-Beral H., Callet-Bauchu E., Salles G., Sabatier L., Delic J., and Gilson E. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111 (2007) 2388-2391
119. Terrin L., Dolcetti R., Corradini I., Indraccolo S., Col J.D., Bertorelle R., Bonaldi L., Esposito G., and De Rossi A. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int. J. Cancer 121 (2007) 576-587
120. El-Daly H., Kull M., Zimmermann S., Pantic M., Waller C.F., and Martens U.M. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105 (2005) 1742-1749
121. Hurley L.H., Wheelhouse R.T., Sun D., Kerwin S.M., Salazar M., Fedoroff O.Y., Han F.X., Han H., Izbicka E., and Von Hoff D.D. G-quadruplexes as targets for drug design. Pharmacol. Ther. 85 (2000) 141-158
122. Neidle S., and Read M.A. G-quadruplexes as therapeutic targets. Biopolymers 56 (2000) 195-208
123. Tauchi T., Shin-ya K., Sashida G., Sumi M., Okabe S., Ohyashiki J.H., and Ohyashiki K. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25 (2006) 5719-5725
124. Burger A.M., Dai F., Schultes C.M., Reszka A.P., Moore M.J., Double J.A., and Neidle S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 65 (2005) 1489-1496
125. Gunaratnam M., Greciano O., Martins C., Reszka A.P., Schultes C.M., Morjani H., Riou J.F., and Neidle S. Mechanism of acridine-based telomerase inhibition and telomere shortening. Biochem. Pharmacol. 74 (2007) 679-689
126. Gowan S.M., Heald R., Stevens M.F., and Kelland L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 60 (2001) 981-988
127. Gavathiotis E., Heald R.A., Stevens M.F., and Searle M.S. Drug recognition and stabilisation of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat. J. Mol. Biol. 334 (2003) 25-36
128. Salvati E., Leonetti C., Rizzo A., Scarsella M., Mottolese M., Galati R., Sperduti I., Stevens M.F., D'Incalci M., Blasco M., Chiorino G., Bauwens S., Horard B., Gilson E., Stoppacciaro A., Zupi G., and Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 117 (2007) 3236-3247
129. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.T., Richardson P., Gryaznov S., Munshi N.C., and Anderson K.C. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63 (2003) 6187-6194
130. Wang E.S., Wu K., Chin A.C., Chen-Kiang S., Pongracz K., Gryaznov S., and Moore M.A. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103 (2004) 258-266
131. Vonderheide R.H. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 90 (2008) 173-180
132. Hermine O., Bouscary D., Gessain A., Turlure P., Leblond V., Franck N., Buzyn-Veil A., Rio B., Macintyre E., Dreyfus F., et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332 (1995) 1749-1751
133. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., and Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76 (1990) 1704-1709
134. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., and Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
135. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., and Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77 (1991) 1080-1086
136. Xu D., Gruber A., Peterson C., and Pisa P. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 10 (1996) 1354-1357
137. Pendino F., Flexor M., Delhommeau F., Buet D., Lanotte M., and Segal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6662-6667
138. Pendino F., Dudognon C., Delhommeau F., Sahraoui T., Flexor M., Bennaceur-Griscelli A., Lanotte M., and Segal-Bendirdjian E. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene 22 (2003) 9142-9150
139. Pendino F., Hillion J., Dudognon C., Delaunay J., Mourah S., Podgorniak M.P., Lafon I., Chomienne C., Lanotte M., Dombret H., Rousselot P., and Segal-Bendirdjian E. Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia 20 (2006) 599-603
140. Pendino F., Sahraoui T., Lanotte M., and Segal-Bendirdjian E. A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation. Leukemia 16 (2002) 826-832
141. Tarkanyi I., Dudognon C., Hillion J., Pendino F., Lanotte M., Aradi J., and Segal-Bendirdjian E. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 19 (2005) 1806-1811
142. Tauchi T., Nakajima A., Sashida G., Shimamoto T., Ohyashiki J.H., Abe K., Yamamoto K., and Ohyashiki K. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin. Cancer Res. 8 (2002) 3341-3347
143. Yamada O., Kawauchi K., Akiyama M., Ozaki K., Motoji T., Adachi T., and Aikawa E. Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk. Lymphoma 49 (2008) 1168-1177
144. Bakalova R., Ohba H., Zhelev Z., Kubo T., Fujii M., Ishikawa M., Shinohara Y., and Baba Y. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. FEBS Lett. 564 (2004) 73-84
145. Tarkanyi I., Horvath A., Szatmari I., Eizert H., Vamosi G., Damjanovich S., Segal-Bendirdjian E., and Aradi J. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett. 579 (2005) 1411-1416
146. Takakura M., Kyo S., Inoue M., Wright W.E., and Shay J.W. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol. 25 (2005) 8037-8043
147. Wang J., Xie L.Y., Allan S., Beach D., and Hannon G.J. Myc activates telomerase. Genes Dev. 12 (1998) 1769-1774
148. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., and Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21 (1999) 220-224
149. Oh S., Song Y.H., Yim J., and Kim T.K. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 19 (2000) 1485-1490
150. Gunes C., Lichtsteiner S., Vasserot A.P., and Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 60 (2000) 2116-2121
151. Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., Ariga H., and Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28 (2000) 669-677
152. Xu D., Popov N., Hou M., Wang Q., Bjorkholm M., Gruber A., Menkel A.R., and Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3826-3831
153. Won J., Yim J., and Kim T.K. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem. 277 (2002) 38230-38238
154. Chang J.T., Yang H.T., Wang T.C., and Cheng A.J. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. Mol. Carcinog. 44 (2005) 183-192
155. Goueli B.S., and Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 22 (2003) 6098-6103
156. Oh S., Song Y., Yim J., and Kim T.K. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J. Biol. Chem. 274 (1999) 37473-37478
157. Xiao X., Phogat S.K., Sidorov I.A., Yang J., Horikawa I., Prieto D., Adelesberger J., Lempicki R., Barrett J.C., and Dimitrov D.S. Identification and characterization of rapidly dividing U937 clones with differential telomerase activity and gene expression profiles: role of c-Myc/Mad1 and Id/Ets proteins. Leukemia 16 (2002) 1877-1880
158. Xiao X., Athanasiou M., Sidorov I.A., Horikawa I., Cremona G., Blair D., Barret J.C., and Dimitrov D.S. Role of Ets/Id proteins for telomerase regulation in human cancer cells. Exp. Mol. Pathol. 75 (2003) 238-247
159. Yatabe N., Kyo S., Maida Y., Nishi H., Nakamura M., Kanaya T., Tanaka M., Isaka K., Ogawa S., and Inoue M. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23 (2004) 3708-3715
160. Nishi H., Nakada T., Kyo S., Inoue M., Shay J.W., and Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24 (2004) 6076-6083
161. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., and Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23 (2004) 1949-1956
162. Yin L., Hubbard A.K., and Giardina C. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J. Biol. Chem. 275 (2000) 36671-36675
163. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., Chauhan D., Richardson P., Munshi N.C., and Anderson K.C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62 (2002) 3876-3882
164. Crowe D.L., Nguyen D.C., Tsang K.J., and Kyo S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res. 29 (2001) 2789-2794
165. Won J., Yim J., and Kim T.K. Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells. FASEB J. 16 (2002) 1943-1945
166. Kanaya T., Kyo S., Hamada K., Takakura M., Kitagawa Y., Harada H., and Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6 (2000) 1239-1247
167. Xu D., Wang Q., Gruber A., Bjorkholm M., Chen Z., Zaid A., Selivanova G., Peterson C., Wiman K.G., and Pisa P. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19 (2000) 5123-5133
168. Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., Kogan I., Braunstein I., Tzukerman M., Ginsberg D., and Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. J. Biol. Chem. 279 (2004) 50976-50985
169. Racek T., Mise N., Li Z., Stoll A., and Putzer B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J. Biol. Chem. 280 (2005) 40402-40405
170. Crowe D.L., and Nguyen D.C. Rb and E2F-1 regulate telomerase activity in human cancer cells. Biochim. Biophys. Acta 1518 (2001) 1-6
171. Kyo S., Takakura M., Kanaya T., Zhuo W., Fujimoto K., Nishio Y., Orimo A., and Inoue M. Estrogen activates telomerase. Cancer Res. 59 (1999) 5917-5921
172. Misiti S., Nanni S., Fontemaggi G., Cong Y.S., Wen J., Hirte H.W., Piaggio G., Sacchi A., Pontecorvi A., Bacchetti S., and Farsetti A. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. 20 (2000) 3764-3771
173. Nanni S., Narducci M., Della Pietra L., Moretti F., Grasselli A., De Carli P., Sacchi A., Pontecorvi A., and Farsetti A. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J. Clin. Invest. 110 (2002) 219-227
174. Wang Z., Kyo S., Takakura M., Tanaka M., Yatabe N., Maida Y., Fujiwara M., Hayakawa J., Ohmichi M., Koike K., and Inoue M. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 60 (2000) 5376-5381
175. Li H., and Liu J.-P. Mechanisms of action of TGF-b in cancer: evidence for Smad3 as a repressor of the hTERT gene. Ann. N. Y. Acad. Sci. 1114 (2007) 56-68
176. Hu B., Tack D.C., Liu T., Wu Z., Ullenbruch M.R., and Phan S.H. Role of Smad3 in the regulation of rat telomerase reverse transcriptase by TGFbeta. Oncogene 25 (2006) 1030-1041
177. Li H., Xu D., Li J., Berndt M.C., and Liu J.P. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 281 (2006) 25588-25600
178. Dimri G.P., Martinez J.L., Jacobs J.J., Keblusek P., Itahana K., Van Lohuizen M., Campisi J., Wazer D.E., and Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 62 (2002) 4736-4745
179. Itahana K., Zou Y., Itahana Y., Martinez J.L., Beausejour C., Jacobs J.J., Van Lohuizen M., Band V., Campisi J., and Dimri G.P. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23 (2003) 389-401
180. Lee S.H., Kim J.W., Lee H.W., Cho Y.S., Oh S.H., Kim Y.J., Jung C.H., Zhang W., and Lee J.H. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene 22 (2003) 381-391
181. Saito M., Nakagawa K., Hamada K., Hirose S., Harada H., Kohno S., Nagato S., and Ohnishi T. Introduction of p16INK4a inhibits telomerase activity through transcriptional suppression of human telomerase reverse transcriptase expression in human gliomas. Int. J. Oncol. 24 (2004) 1213-1220
182. Kanzawa T., Komata T., Kyo S., Germano I.M., Kondo Y., and Kondo S. Down-regulation of telomerase activity in malignant glioma cells by p27KIP1. Int. J. Oncol. 23 (2003) 1703-1708
183. Lee S.H., Kim J.W., Oh S.H., Kim Y.J., Rho S.B., Park K., Park K.L., and Lee J.H. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett. 579 (2005) 1027-1033
184. Endoh T., Tsuji N., Asanuma K., Yagihashi A., and Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp. Cell Res. 305 (2005) 300-311
185. Oh S.T., Kyo S., and Laimins L.A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 75 (2001) 5559-5566
186. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380 (1996) 79-82
187. Shammas M.A., Koley H., Bertheau R.C., Neri P., Fulciniti M., Tassone P., Blotta S., Protopopov A., Mitsiades C., Batchu R.B., Anderson K.C., Chin A., Gryaznov S., and Munshi N.C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22 (2008) 1410-1418
188. Asai A., Oshima Y., Yamamoto Y., Uochi T.A., Kusaka H., Akinaga S., Yamashita Y., Pongracz K., Pruzan R., Wunder E., Piatyszek M., Li S., Chin A.C., Harley C.B., and Gryaznov S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63 (2003) 3931-3939
189. Li S., Nosrati M., and Kashani-Sabet M. Knockdown of telomerase RNA using hammerhead ribozymes and RNA interference. Methods Mol. Biol. 405 (2007) 113-131
190. Saretzki G., Ludwig A., von Zglinicki T., and Runnebaum I.B. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8 (2001) 827-834
191. Yeo M., Rha S.Y., Jeung H.C., Hu S.X., Yang S.H., Kim Y.S., An S.W., and Chung H.C. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int. J. Cancer 114 (2005) 484-489
192. Roth A., Vercauteren S., Sutherland H.J., and Lansdorp P.M. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 17 (2003) 2410-2417
193. Nakajima A., Tauchi T., Sashida G., Sumi M., Abe K., Yamamoto K., Ohyashiki J.H., and Ohyashiki K. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17 (2003) 560-567
194. Sumi M., Tauchi T., Sashida G., Nakajima A., Gotoh A., Shin-Ya K., Ohyashiki J.H., and Ohyashiki K. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int. J. Oncol. 24 (2004) 1481-1487
195. Shammas M.A., Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., and Munshi N.C. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10 (2004) 770-776
196. Tauchi T., Shin-Ya K., Sashida G., Sumi M., Nakajima A., Shimamoto T., Ohyashiki J.H., and Ohyashiki K. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22 (2003) 5338-5347
197. Beatty G.L., and Vonderheide R.H. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev. Vaccines 7 (2008) 881-887
198. Datta A., Bellon M., Sinha-Datta U., Bazarbachi A., Lepelletier Y., Canioni D., Waldmann T.A., Hermine O., and Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108 (2006) 1021-1029
199. Strahl C., and Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16 (1996) 53-65
200. Love W.K., Deangelis J.T., Berletch J.B., Phipps S.M., Andrews L.G., Brouillette W.J., Muccio D.D., and Tollefsbol T.O. The novel retinoid, 9cUAB30, inhibits telomerase and induces apoptosis in HL60 cells. Transl. Oncol. 1 (2008) 148-152